Real-world Impact of Bridging Therapy on Outcomes of Ide-cel for Myeloma in the U.S. Myeloma Immunotherapy Consortium

Ferreri C, Hildebrandt M, Hashmi H, Shune L, McGuirk J, Sborov D . Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023; 13(1):117. PMC: 10412575. DOI: 10.1038/s41408-023-00886-8. View

Das R, OConnor R, Grupp S, Barrett D . Lingering effects of chemotherapy on mature T cells impair proliferation. Blood Adv. 2020; 4(19):4653-4664. PMC: 7556159. DOI: 10.1182/bloodadvances.2020001797. View

Bhaskar S, Dholaria B, Sengsayadeth S, Savani B, Oluwole O . Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022; 3(Suppl 1):39-45. PMC: 9175845. DOI: 10.1002/jha2.335. View

Hansen D, Sidana S, Peres L, Colin Leitzinger C, Shune L, Shrewsbury A . Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023; 41(11):2087-2097. PMC: 10082273. DOI: 10.1200/JCO.22.01365. View

Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S . Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716. DOI: 10.1056/NEJMoa2024850. View

Samur M, Fulciniti M, Aktas Samur A, Bazarbachi A, Tai Y, Prabhala R . Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021; 12(1):868. PMC: 7870932. DOI: 10.1038/s41467-021-21177-5. View

Kumar S, Paiva B, Anderson K, Durie B, Landgren O, Moreau P . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346. DOI: 10.1016/S1470-2045(16)30206-6. View

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

Zafar A, Huang C, Lo M, Arora S, Chung A, Wong S . Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2023; 29(8):504.e1-504.e7. DOI: 10.1016/j.jtct.2023.05.016. View

10.

Gust J, Hay K, Hanafi L, Li D, Myerson D, Gonzalez-Cuyar L . Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017; 7(12):1404-1419. PMC: 5718945. DOI: 10.1158/2159-8290.CD-17-0698. View

11.

Das R, Vernau L, Grupp S, Barrett D . Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers. Cancer Discov. 2019; 9(4):492-499. PMC: 6676489. DOI: 10.1158/2159-8290.CD-18-1314. View